Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
894 A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models
Compose a Response to This Article
Other responses
No responses have been published for this article.